Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 18/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.65 |
| ▸ | CTSG | P08311 | 1/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409986 | 0.84 | CMA1 (0.77) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3654773 | 0.80 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL404228 | 0.79 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999231 | 0.79 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL409547 | 0.79 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL23752344 | 0.79 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL13009082 | 0.79 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL31476750 | 0.79 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998105 | 0.79 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998748 | 0.73 | CMA1 (0.78) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.